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Abstract
Elevated nighttime blood pressure (BP) and heart rate (HR), increased BP and HR variabili-
ty, and altered diurnal variations of BP and HR (nighttime dipping and morning surge) in pa-
tients with systemic hypertension are each associated with increased adverse
cardiovascular events. However, there are no reports on the effect of hypertension treat-
ment on these important hemodynamic parameters in the growing population of hyperten-
sive patients with atherosclerotic coronary artery disease (CAD). This was a pre-specified
subgroup analysis of the INternational VErapamil SR-Trandolapril STudy (INVEST), which
involved 22,576 clinically stable patients aged50 years with hypertension and CAD ran-
domized to either verapamil SR- or atenolol-based hypertension treatment strategies. The
subgroup consisted of 117 patients undergoing 24-hour ambulatory monitoring at baseline
and after 1 year of treatment. Hourly systolic and diastolic BP (SBP and DBP) decreased
after 1 year for both verapamil SR- and atenolol-based treatment strategies compared with
baseline (P<0.0001). Atenolol also decreased hourly HR (P<0.0001). Both treatment strat-
egies decreased SBP variability (weighted standard deviation: P = 0.012 and 0.021, respec-
tively). Compared with verapamil SR, atenolol also increased the prevalence of BP and HR
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nighttime dipping among prior non-dippers (BP: OR = 3.37; 95% CI: 1.26 – 8.97; P = 0.015;
HR: OR = 4.06; 95% CI: 1.35-12.17; P = 0.012) and blunted HRmorning surge (+2.8 vs.
+4.5 beats/min/hr; P = 0.019). Both verapamil SR- and especially atenolol-based strategies
resulted in favorable changes in ambulatory monitoring parameters that have been previ-




Studies of ambulatory blood pressure (BP) and heart rate (HR) monitoring in hypertension pa-
tients have shown that abnormalities in certain hemodynamic parameters are associated with
increased adverse cardiovascular events: elevated nighttime BP and HR [1–7], increased BP
and HR variability [8–13], blunting of nighttime dipping [1,4,14–19], and, although somewhat
controversial, augmentation of morning surge of BP and HR [19–25]. There are reports on the
effect of hypertension treatment on some of these important hemodynamic parameters in the
generalized hypertensive population [26–30]. However, there are no reports on any of these pa-
rameters focused on the growing population of patients with hypertension and concurrent ath-
erosclerotic coronary artery disease (CAD).
The INternational VErapamil SR-Trandolapril STudy (INVEST) was a prospective, ran-
domized, open label, blinded end-point study of 22,576 patients aged50 years with clinically
stable hypertension and CAD. INVEST compared outcomes using verapamil SR- vs. atenolol-
based hypertension treatment strategies [31]. The primary outcome was the first occurrence of
all-cause death, nonfatal myocardial infarction (MI), or nonfatal stroke. As previously reported
[32], both strategies provided excellent office-measured BP control (>70% patients achieved
office-based BP<140/90 mmHg) and were equivalent for reducing mortality and major mor-
bidity. Here we report the results of a pre-specified detailed analysis focusing on 117 INVEST
patients who underwent 24-hour ambulatory monitoring prior to randomization (“baseline”)
and after 1 year of treatment to determine the effect of each treatment strategy on the above
important hemodynamic parameters.
Materials and Methods
The protocol for this trial and supporting TREND checklist are available as supporting infor-
mation; see S1 TREND Checklist and S1 Protocol.
Ethics Statement
The study was performed in accordance with the Declaration of Helsinki and was approved by
the University of Florida Institutional Review Board, Gainesville, Florida (Protocol #337–2008,
approved 5/22/1997). INVEST is registered at Clinicaltrials.gov, identifier NCT00133692. At
the time of patient recruitment, clinicaltrials.gov was in development. The registry was made
public in 2000, at which time primarily NIH-funded trials were registered. Our trial was regis-
tered in 2005 to comply with forthcoming expansion of registration requirements. The authors
confirm that all ongoing and related trials for this drug/intervention are registered. All patients
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provided written informed consent. Patient visits occurred between 09/02/1997 and 02/14/
2003.
The INVEST design, methods and principal results have been described in detail [31,32].
The study was performed in accordance with the Declaration of Helsinki and was approved by
local ethics committees. All patients provided written informed consent. Briefly, patients with
clinically stable hypertension and CAD were randomized to either a verapamil SR- or an ateno-
lol-based treatment strategy. Additional nighttime dosing of the study drug and subsequent ad-
dition of trandolapril with or without hydrochlorothiazide (HCTZ) for the verapamil SR group
and addition of HCTZ with or without trandolapril for the atenolol group was recommended if
needed for BP control. Trandolapril was also recommended for patients with history of heart
failure, diabetes, or renal insufficiency. The BP treatment goal was an office-based BP<140/90
mmHg (<130/85 mmHg for patients with diabetes and/or renal insufficiency). All adjustments
in drugs were completed within 6 months of randomization.
Ambulatory monitoring was conducted in 141 INVEST patients selected by clinics with in-
terest and expertise in ambulatory monitoring in Hungary and the United States (Meditech
ABPM, Meditech Ltd., Budapest, Hungary; SpaceLabs Model 90207, SpaceLabs Medical Inc.,
Issaquah, WA, USA). The monitors were validated according to international protocols and
measured BP and HR every 15 min from 06:00–22:00 (“daytime” hours) and every 20 min
from 22:01–05:59 (“nighttime” hours). The following criteria were mandatory for inclusion
into ambulatory monitoring data analysis: (1) adequate technical quality for85% of the
24-hour recording period, (2)<3 consecutive hours without valid measurements, (3)<4 non-
consecutive hours without valid measurements.
Statistical Analyses
The individual BP and HR measurements for each subject were averaged into 1-hour epochs
prior to subsequent analysis. Pulse pressure was defined as the difference between systolic (S)
BP and diastolic (D) BP. To quantify BP and HR variability, we calculated the weighted stan-
dard deviation (wSD) and weighted coefficient of variation (wCV) [33,34].
Nighttime dipper status for SBP, DBP, and HR was defined as a decrease in SBP, DBP, or
HR, respectively, by10% during the hours 20:00–02:00 [18]. However, because there is no
consensus for the definition of BP or HR morning surges [24,35], we calculated the difference
between the minimum and maximum BP and HR, respectively, between 02:00–10:00. We also
calculated the average and hourly maximum slope of the BP and HR curve between 20:00–
02:00 and between 02:00–10:00.
Data for continuous variables are summarized as mean±SD or median with interquartile
range, based upon symmetry of distribution. Categorical variables are presented as number
(percentages). Comparisons between baseline and post–1-year treatment values of BP and HR
were performed using the paired Student t-test (2-tailed). Independent t test was used for com-
parisons between treatment strategies. Repeated measure analysis with autoregressive 1 covari-
ance structure was also performed to assess the difference between the 2 treatment groups and
between the baseline and post–1-year visits, while adjusting for covariates including age, gen-
der, smoking, history of MI, stroke or transient ischemic attack, and diabetes. The McNemar
test was used to compare the proportion of dippers before and after treatment. Multivariable
logistic regression was used to assess the predictors of dipper status and change in dipper status
after adjusting for covariates. All variables with a univariate P value of<0.2 were considered
for stepwise selection for the logistic regression model. Variables with P<0.05 were retained in
the final model. Odds ratios and 95% confidence intervals are presented. Hosmer-Lemeshow
test of goodness-of-fit was performed to evaluate the model fit. All analysis was performed
INVEST Ambulatory Monitoring Substudy
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using SAS version 9.3 (SAS Institute Inc, Cary, North Carolina). P-values of<0.05 were con-
sidered statistically significant.
Results
The 141 patients with ambulatory monitoring measurements were recruited from 13 sites, rep-
resenting a 68% participation rate for this substudy. Technically valid BP and HR recordings
were available in 117 patients both at baseline and after 1 year of treatment (Fig 1). Baseline
clinical characteristics were similar for these 117 patients comparing treatment strategies
(Table 1). Additionally, baseline office SBP, DBP, and HR were similar for these patients and
were also similar to the remaining 22,459 INVEST patients (Fig 2).
However, several clinical characteristics of the ambulatory monitoring patients, as a group,
differed significantly from the remaining, non-ambulatory monitoring INVEST patients
(Table 1). The ambulatory monitoring patients were slightly younger and less obese but had a
higher prevalence of other comorbidities (e.g., MI, left ventricular hypertrophy, heart failure,
and hypercholesterolemia) compared with remaining INVEST patients. To explore whether
the difference in characteristics affected applicability of the subgroup analysis to the remaining
INVEST patients, we created a 3:1 frequency-matched patient dataset (N = 423) for the ambu-
latory monitoring patients, using the remaining INVEST patients as the source. This dataset
was based upon age (decades), gender, and maximized a match for the remaining 23 character-
istics. The total number of characteristics successfully matched was 14/25. Using this dataset,
we then compared the office BP by treatment strategy throughout the study visits spanning 48
months and found no statistical difference based on treatment strategy (all P values>0.05)
(Fig 3). Therefore, it seems that there was no significant selection bias into the subgroup analy-
sis and that the results of the subgroup analysis should be reasonably applicable to the remain-
ing INVEST patients.
After 1 year of treatment, 24/63 patients randomized to the verapamil SR-based treatment
strategy (38.1%) and 19/54 patients randomized to the atenolol-based treatment strategy
(35.2%) had increased to a final twice-daily dosing, as directed by protocol, to optimize man-
agement of hypertension (Table 2; P = 0.75 for proportion). Additionally, by 6 months of
Fig 1. Consort diagram showing selection of INVEST patients for the ambulatory monitoring
substudy analysis. The subgroup consisted of 141 patients undergoing 24-hour ambulatory monitoring at
baseline and after 1 year of treatment. Patients were excluded if their blood pressure and heart rate
recordings did not meet the criteria for inclusion (adequate technical quality85% of the 24-hour recording
period,<3 consecutive hours without valid measurements, and<4 non-consecutive hours without valid
measurements).
doi:10.1371/journal.pone.0122726.g001
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treatment, 42/63 patients randomized to the verapamil SR-based treatment strategy (66.7%)
had trandolapril added per protocol. However, 0/54 patients randomized to the atenolol-based
treatment strategy (0%) had trandolapril added per protocol (P<0.0001). Finally, 20/63
(31.7%) and 33/54 (61.1%) had HCTZ added, respectively (P = 0.0015).
After 1-year of treatment, both verapamil SR- and atenolol-based strategies similarly de-
creased ambulatory BP vs. baseline, and this decrease persisted throughout 24 hours for each
strategy (P<0.0001 for SBP and DBP from the repeated measure analysis; Figs 2 and 4). Addi-
tionally, there was a corresponding decrease in the 24-hour area under the BP curve for both
Table 1. Baseline Clinical Characteristics of Ambulatory Monitoring Patients According to Treatment Strategy, and Compared to Remaining, Non-





Characteristic (N = 63) (N = 54) (N = 22,459) P-valueb
Age, years 60.8 (7.5) 62.3 (7.5) 65.7 (9.8) < 0.0001
Women 32 (50.8) 32 (59.3) 11706 (52.1) 0.58
BMI, kg/m2 27.8 (3.8) 28.4 (4.4) 29.2 (7.1) 0.005
History of:
Myocardial infarction 28 (44.4) 23 (42.6) 7167 (31.9) 0.007
Angina pectoris 46 (73.0) 40 (74.1) 14959 (66.6) 0.11
Coronary revascularization (CABG and/or PCI) 3 (4.8) 7 (12.96) 6156 (27.4) <0.0001
Stroke/TIA 6 (9.5) 5 (9.3) 1618 (7.2) 0.36
LVH 25 (39.7) 26 (48.2) 4897 (21.8) < 0.0001
Arrhythmia 2 (3.2) 6 (11.1) 1592 (7.1) 0.92
Heart failure (class I-III) 3 (4.8) 5 (9.3) 1248 (5.6) 0.02
Peripheral vascular disease 4 (6.4) 2 (3.7) 2693 (12.0) 0.04
Smoking 24 (38.1) 19 (35.2) 10411 (46.4) 0.038
Diabetes 12 (19.1) 12 (22.2) 6376 (28.4) 0.059
Hypercholesterolemia 47 (74.6) 36 (66.7) 12510 (55.7) 0.0009
Renal impairment 1 (1.6) 1 (1.9) 422 (1.9) 0.89
Antihypertensive Therapy (prior to randomization)
Beta blockerc 0 0 0 N/A
Calcium antagonist 31 (49.2) 31 (57.4) 8027 (35.7) 0.0001
Diuretic 23 (36.5) 24 (44.4) 7346 (32.7) 0.086
Central acting 11 (17.5) 8 (14.8) 1033 (4.6) <0.0001
ACE inhibitor 47 (74.6) 40 (74.1) 9962 (44.4) <0.0001
Alpha blocker 4 (6.4) 6 (11.1) 1648 (7.3) 0.62
Other class 2 (3.2) 2 (3.7) 4358 (19.4) <0.0001
Data are presented as mean (SD) or number (percent).
BMI, body mass index; CABG, coronary artery bypass graft; INVEST, INternational VErapamil SR-Trandolapril STudy; LVH, left ventricular hypertrophy;
PCI, percutaneous coronary intervention; SD, standard deviation; TIA, transient ischemic attack.
aComparing ambulatory monitoring study patients randomized to verapamil SR- vs. atenolol-based treatment strategies, P value uniformly nonsignificant.
bComparing all ambulatory monitoring INVEST study patients with remaining, non-ambulatory monitoring patients.
cPatients taking beta-blockers within 2 weeks of randomization or taking beta-blockers for an MI that occurred in the previous 12 months were excluded
from INVEST to avoid withdrawal phenomena in patients randomized to the verapamil-based treatment strategy [31].
doi:10.1371/journal.pone.0122726.t001
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strategies (verapamil SR: 2990/1733 vs. 2854/1673 mmHg hr, P = 0.011 and 0.034, respectively;
atenolol: 3059/1765 vs. 2895/1691 mmHg hr, P = 0.0016 and 0.067, respectively). Moreover,
after treatment, HR was consistently decreased among atenolol patients (P<0.0001 from the
repeated measure analysis; Figs 2 and 4; area under HR curve: 1615 vs. 1498 beats hr/min,
P = 0.0028) but unchanged among verapamil SR patients (P = 0.49; 1685 vs. 1667 beats hr/min,
P = 0.49). Interestingly, pulse pressure at baseline was relatively low for each strategy and de-
creased for both after 1 year of treatment (verapamil SR: 55.5 vs. 51.8 mmHg, P = 0.022; ateno-
lol: 56.6 vs. 52.5 mmHg, P = 0.010).
The wSD for SBP decreased with both treatment strategies (verapamil SR: 14.34 vs.
13.00 mmHg, P = 0.012; atenolol: 15.18 vs. 13.50 mmHg, P = 0.021). Also, the wCV for SBP
decreased numerically—but not to statistical significance—with both strategies (11.01 vs.
10.52, P = 0.36; 11.46 vs. 10.76, P = 0.63, respectively). Conversely, the wSD and wCV for
DBP and HR did not change with either treatment strategy.
At baseline, 68% and 56% of the patients were BP dippers within the verapamil-SR and the
atenolol strategies, respectively (P = 0.14, comparing strategies), while 65% and 69% of the pa-
tients were BP dippers after treatment, respectively (P = 0.61, comparing strategies). However,
Fig 2. Office-based and 24-hour ambulatory monitoring systolic blood pressure (SBP), diastolic blood
pressure (DBP), and heart rate (HR) at baseline and following 1 year of treatment. The baseline data
contain both verapamil SR- and atenolol-based strategies combined, while the data following 1 year of
treatment is individualized to treatment strategy. For comparison, baseline office-based data for the
remaining INVEST patients, who did not have ambulatory blood pressure monitoring, are shown to the left.
Horizontal line through each box represents median; bottom and top of box represent first and third quartiles;
the whiskers represent minimum and maximum of all data.
doi:10.1371/journal.pone.0122726.g002
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29.6% of atenolol BP non-dipper patients vs. 11.1% of verapamil SR BP non-dipper patients
changed to dippers after 1-year (P = 0.028), and 25.9% vs. 7.9% changed from HR non-dipper
to dipper, respectively (P = 0.0007). Additionally, the average slope of the nighttime SBP curve
was less steep (i.e., blunting of nighttime SBP dipping) for the verapamil SR patients after 1
Fig 3. Office-based systolic and diastolic blood pressure based upon treatment strategy among 423
frequency-matched INVEST patients who did not have ambulatory blood pressuremonitoring. The
minimum P values were 0.12 and 0.09, respectively.
doi:10.1371/journal.pone.0122726.g003
Table 2. Study Drug Use in Patients Randomized to Verapamil SR- or Atenolol-Based Treatment Strategy at Baseline (Immediately Following Ran-
domization) and After 1 Year of Treatment.















No: 61 No: 2 No: 37 No: 24 <0.0001 0.75
Dose: 240 Dose: 360 Dose: 180 Dose: 360
+ Trandolapril No: 7 No: 2 No: 20 No: 22 <0.0001 <0.0001
Dose: 2 Dose: 4 Dose: 2 Dose: 4
+ HCTZ No: 3 No: 0 No: 16 No: 4 0.0001 0.0015
Dose: 25 Dose: N/A Dose: 25 Dose: 50
Atenolol (N = 54) No: 51 No: 3 No: 32 No: 19 <0.0001
Dose: 50 Dose: 50 Dose: 50 Dose: 100
+ HCTZ No: 2 No: 1 No: 28 No: 5 <0.0001
Dose:25 Dose: 25 Dose: 25 Dose: 50
+ Trandolapril No: 6 No: 1 No: 0 No: 0 N/A
Dose: 2 Dose: 4 Dose: N/A Dose: N/A
Doses are mg/day.
N/A = not applicable.
a2 patients randomized to the verapamil SR strategy and 3 patients randomized to the atenolol strategy discontinued the study drug due to side effects.
bP-values using Wilcoxon-rank sum test comparing the doses between once daily (QD) and twice daily (BID) pts.
cComparing ambulatory monitoring study patients randomized to verapamil SR- vs. atenolol-based treatment strategies for BID dosing of study drug,
addition of trandolapril and addition of hydrochlorothiazide (HCTZ), per INVEST protocol.
doi:10.1371/journal.pone.0122726.t002
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Fig 4. Twenty-four-hour ambulatory systolic blood pressure (SBP), diastolic blood pressure (DBP),
and heart rate by strategy, both at baseline and after 1 year of treatment. Individual data points represent
mean values. Nighttime dipping was determined over the time interval 20:00–02:00 and morning surge over
the interval 02:00–10:00.
doi:10.1371/journal.pone.0122726.g004
INVEST Ambulatory Monitoring Substudy
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year of treatment compared with baseline (-2.1 vs. -4.3 mmHg/hr, respectively; P = 0.026) (Fig
4). However, after treatment, there was no significant change in the average slope of the night-
time SBP curve for the atenolol patients, no significant change in the average slope of the night-
time DBP curve for either drug, and no significant changes in maximum slopes for either drug
for either nighttime SBP or DBP curves (Fig 4). Finally, there was no significant change after
treatment in the average or maximum slopes of the nighttime HR curve for either drug (Fig 4).
Logistic regression showed that BP dipper status at baseline strongly predicted 1-year treat-
ment dipper status; patients who were dippers at baseline were almost 3 times as likely to be a
dipper after 1 year of treatment, compared to non-dippers (OR: 2.93; 95% CI: 1.30–6.57;
P = 0.0094). For HR dipper status, baseline dipper status was marginally significant (OR: 2.11;
0.88–5.06; P = 0.094). Treatment with the atenolol-based strategy was a significant predictor
for changing from a BP non-dipper to a dipper (OR: 3.37; 95% CI: 1.26–8.97; P = 0.015) and
HR non-dipper to a dipper (OR: 4.06; 95% CI: 1.35–12.17; P = 0.012). Interestingly, baseline
demographics such as age, gender, history of MI, heart failure, and diabetes did not predict
changes in dipper status. The P values for Hosmer-Lemeshow test of goodness-of-fit were uni-
formly>0.05.
There were no significant differences, augmentation, or blunting of BP morning surge com-
paring strategies either at baseline or at 1 year (Fig 4). All BP slopes were similar. However,
there was blunting of HR morning surge for atenolol vs. verapamil SR patients at 1 year (Fig 4;
+2.8 vs. +4.5 beats/min/hr, respectively; P = 0.019).
Discussion
The results of this substudy of the INVEST indicate that, for patients with hypertension and
CAD, both verapamil SR- and atenolol-based treatment strategies provide 24-hour BP control
with positive effects on important hemodynamic parameters that have been previously associ-
ated with adverse cardiovascular events. These positive effects may have contributed to limiting
adverse events and include: (1) a consistent decrease in nighttime BP; (2) a decrease in 24-hour
SBP variability; and (3) no overt negative effect on diurnal BP variations. Additionally, atenolol
provided a consistent decrease in nighttime HR, a relative increase in change from non-dipper
to dipper status for both BP and HR, and a blunting of HR morning surge. These latter effects
may have contributed to the limitation in adverse events observed among congestive heart fail-
ure patients receiving the atenolol-based treatment strategy in the INVEST [32].
The ambulatory monitoring used in this substudy provided a more continuous measure-
ment of BP and HR for these patients over 24 hours compared with the remaining INVEST pa-
tients, who had office BP and HR measured at one time point during scheduled visits.
Ambulatory monitoring in clinical trials has been shown to provide enhanced precision (allow-
ing for reduced sample size and/or increased study power), elimination of observer bias, and
identification of individuals with “white coat,” “masked” and even true “treatment resistant”
hypertension [36]. Moreover, ambulatory monitoring before the start of lifelong drug treat-
ment may lead to more appropriate targeting of treatment, particularly around the diagnostic
threshold [37].
Unfortunately, the recently published JNC8 Report [38] did not address the use of ambula-
tory monitoring for BP management, and similarly did not specifically address patients with
hypertension and CAD as a special population. Thus the 24-hour effects of antihypertensive
drugs on the growing population of patients with hypertension and CAD—including issues
such as "masked hypertension,” true "treatment resistant hypertension," and the concept of op-
timizing the target of treatment around the diagnostic threshold—are not addressed by our
most current national hypertension management guidelines.
INVEST Ambulatory Monitoring Substudy
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This substudy has limitations. First, patients undergoing ambulatory monitoring repre-
sented a pre-specified population of interest. However, they were selected by clinics in Hungary
and the United States with interest and expertise in ambulatory monitoring. Additionally, the
patients were not randomly selected and demonstrated some clinical characteristics that dif-
fered from the remaining INVEST patients. Nonetheless, their similarity in remaining baseline
characteristics, baseline BP and HR and the results of our frequency-matched patient dataset
analysis do suggest that the results of the subgroup analysis are reasonably applicable to the re-
maining INVEST patients. Second, day-night blood pressure changes and the classification of
patients into dippers and non-dippers can be poorly reproducible over time [39], which can
limit the applicability of those results. Third, the effect of other non-randomized antihyperten-
sive drugs used in the INVEST (e.g., trandolapril and HCTZ) may have a confounding effect
on the results. Finally, the relatively low baseline pulse pressure and its subsequent decrease for
both strategies may have independently contributed to limiting adverse events in all
INVEST patients.
Limitations notwithstanding, the results of this substudy of INVEST using ambulatory
monitoring demonstrate that both verapamil SR- and especially atenolol-based strategies result
in favorable changes in ambulatory monitoring parameters for patients with hypertension and
CAD that have been previously associated with increased adverse cardiovascular events.
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